Sage Rhino Capital LLC Raises Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Sage Rhino Capital LLC raised its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 14.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,840 shares of the company’s stock after buying an additional 1,538 shares during the quarter. Sage Rhino Capital LLC’s holdings in Takeda Pharmaceutical were worth $157,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Versant Capital Management Inc purchased a new stake in Takeda Pharmaceutical during the 4th quarter valued at $26,000. Wilmington Savings Fund Society FSB bought a new position in shares of Takeda Pharmaceutical during the third quarter valued at about $40,000. BNP Paribas Financial Markets increased its holdings in Takeda Pharmaceutical by 416.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock valued at $46,000 after purchasing an additional 2,596 shares during the period. Smithfield Trust Co raised its position in Takeda Pharmaceutical by 76.9% during the 3rd quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock valued at $49,000 after purchasing an additional 1,490 shares during the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in Takeda Pharmaceutical in the 3rd quarter worth approximately $52,000. 9.17% of the stock is currently owned by institutional investors.

Takeda Pharmaceutical Stock Performance

NYSE:TAK opened at $14.84 on Tuesday. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. Takeda Pharmaceutical Company Limited has a twelve month low of $12.57 and a twelve month high of $15.08. The stock has a market cap of $47.22 billion, a P/E ratio of 37.10, a price-to-earnings-growth ratio of 0.24 and a beta of 0.51. The firm’s fifty day simple moving average is $13.44 and its 200 day simple moving average is $13.89.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, research analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.